Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study

References

• Rosenberg SA, Grimm EA, McGrogan M et al, Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Sciences (WashDC) (1984) 223: 1412–7.
   Google Scholar
• Sosman JA, Kohler PC, Hank JA et al, Repetitive weekly cycles of interleukin-2 (IL-2): II Clinical and immunologic effects of dose, schedule and indomethacin. J Natl Cancer Inst (1988) 80: 1451–61.
   Google Scholar
• Weidmann E, Bergmann L, Stock J et al, Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother (1992) 12: 123–31.
   Google Scholar
• Blay JY, Negrier S, Combaret V et al, Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res (1992) 52: 3317–22.
   Google Scholar
• Nash MA, Ferrandina G, Gordinier M et al, The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer (1992) 6: 93–107.
   Google Scholar
• De Vita F, Orditura M, Auriemma A et al, Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep (1998) 5: 649–52.
   Google Scholar
• Oka M, Yamamoto K, Takahashi M et al, Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. CancerRes (1996) 56: 2776–80.
   Google Scholar
• Belluco C, Nitti D, Frantz M et al, Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol (2000) 7: 133–8.
   Google Scholar
• Nakashima J, Tachibana M, Horiguchi Y et al, Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res (2000) 6: 2702–6.
   Google Scholar
• Mouawad R, Benhammouda A, Rixe O et al, Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumour burden. Clin Cancer Res (1996) 2: 1405–9.
   Google Scholar
• Mouawad R, Antoine EC, Khayat D, Soubrane C, Effect of endogenous interleukin-6 on Fas (APO-1/CD95) receptor expression in advanced melanoma patients. Cytokines Cell Mol Ther (2000) 6: 135–40.
   Google Scholar
• Khayat D, Borel C, Tourani JM et al, Sequential chemoimmu-notherapy with cisplatin, interleukin-2, and interferon α-2a for metastatic melanoma. J Clin Oncol (1993) 11: 2173–80.
   Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A, Reporting results of cancer treatment. Cancer (1981) 47: 207–14.
   Google Scholar
• Breslow A, Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg (1970) 172: 902–8.
   Google Scholar
• American Joint Committee on Cancer. Manual for Staging of Cancer edn 4. Philadelphia, PA: Lippincott, 1992; 143–8.
   Google Scholar
• Kaplan EL, Meier P, Nonparametric estimation for incomplete observation. J Am Stat Assoc (1958) 53: 457–81.
   Google Scholar
• Mantel N, Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep (1966) 5: 163–70.
   Google Scholar
• Kerbel RS, Expression of multi-cytokine resistance and multigrowth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol (1992) 141: 519–24.
   Google Scholar
• Lu C, Kerbel RS, Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 120: 1281–8.
   Google Scholar
• Mouawad R, Khayat D, Merle S et al, Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy. Melanoma Res (1999) 9: 181–8.
   Google Scholar
• Lai R, O’Brien S, Maushouri T et al, Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer (2002) 95: 1071–5.
   Google Scholar
• Andrews B, Shariat SF, Kim JH et al, Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol (2002) 167: 1475–81.
   Google Scholar
• Scambia G, Testa U, Benedetti Panici P et al, Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer (1995) 71: 354–6.
   Google Scholar
• Kallio JP, Tammela TL, Marttinen AT et al, Soluble immunological parameters and early prognosis of renal cell cancer patients. J Exp Clin Cancer Res (2001) 4: 523–8.
   Google Scholar
• Deichmann M, Benner A, Bock M et al, S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer Stage IV melanoma. J Clin Oncol (1999) 17: 1891–6.
   Google Scholar
• Salgado R, Junius S, Benoy I et al, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer (2003) 103: 642–6.
   Google Scholar
• Fayad L, Cabanillas F, Talpaz M et al, High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma (1998) 30: 563–71.
   Google Scholar
• De Vita F, Romano C, Orditura M et al, Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res (2001) 21: 45–52.
   Google Scholar